Ring Closure to â-Turn Mimics via
Copper-Catalyzed Azide/Alkyne
Cycloadditions
Yu Angell and Kevin Burgess*
Chemistry Department, Texas A & M University,
P.O. Box 30012, College Station, Texas 77842
FIGURE 1. Some â-turn nomenclature, semipeptidic mimics
usually prepared via solid-phase reactions, and the solution
phase click strategy featured in this Note.
Received August 2, 2005
Copper-catalyzed azide alkyne cycloadditions of the linear
substrates 1 were used to form the cyclic derivatives 2.
Computational, NMR, and CD analyses of these compounds
indicate that their most favorable conformational states
include type I and type II â-turn conformations. Selectivity
for the dimeric products 6 in these cyclization reactions is
discussed.
FIGURE 2. Substrate and product structures in this study.
R1′ and R2′ denote protected side chains; R1 and R2 are
deprotected ones.
ods to do this. Solid-phase syntheses were used in all our
previous syntheses of dipeptide-containing peptidomi-
metics. These have the advantage of pseudo-dilution
caused by reactive site isolation on solid supports at
moderate to low loading. Solution phase methods, on the
other hand, require ring closure via efficient reactions.
There have been at least two applications of cycloaddition
reactions to ring-close â-turn peptidomimetics,10,11 but
none featuring the copper-catalyzed azide alkyne cy-
cloadditions (i.e., “click reactions”).12 Consequently, this
Note features application of those reactions as depicted
in Figure 2.
Many groups are interested in syntheses of â-turn
peptidomimetics that have potential applications in
medicinal chemistry.1-4 Our focus in this area has been
to constrain dipeptide fragments in appropriate confor-
mations by using macrocyclizations, particularly to form
14-membered rings.5-9 That ring size facilitates confor-
mational arrangements of edge shared C10 systems, one
featuring the dipeptide and the other comprising a
nonpeptidic fragment (Figure 1).
Scheme 1 outlines the preparation of the starting
materials 1. Side chain protection was necessary for the
Lys (Cbz), Glu (Bn), Thr (Bn), Ser (Bn), and Tyr (Bn)
amino acids. These protecting groups render the inter-
mediates relatively lipophilic, hence use of a water-
soluble diimide reagent in the coupling steps facilitated
separation of the products via aqueous extractions.
Finally, the linear precursors 1 were recrystallized and
isolated in an overall average yield of 70%. Thus the
substrates 1 were conveniently accessible in gram amounts
via syntheses that could be performed in parallel.13
Cyclization of the linear precursors gave the “mono-
meric” and “dimeric” products 5 and 6. Two measures
were taken to favor formation of the protected 14-
membered ring products 5: THF solutions of the azides
1 were added to the copper catalyst over 10-14 h via a
syringe pump, and the final concentration was kept low
(approximately 0.001 M). Nevertheless, dimeric products
Many nonpeptidic fragments can be used in the pep-
tidomimetics featured above. This is a means to incor-
porate diversity and to use different chemical reactions
in the ring-closure step. Our bias is to avoid reactions
that make the macrocycles more peptidic (i.e., amide bond
formation) and to favor ones that give the small hetero-
cyclic fragments found in pharmaceuticals. Moreover, we
are currently interested in scalable solution phase meth-
(1) Blomberg, D.; Hedenstrom, M.; Kreye, P.; Sethson, I.; Brick-
mann, K.; Kihlberg, J. J. Org. Chem. 2004, 69, 3055-3508.
(2) Im, I.; Webb, T. R.; Gong, Y.-D.; Kim, J.-I.; Kim, Y.-C. J. Comb.
Chem. 2004, 6, 207-213.
(3) Gu, X.; Cowell, S.; Ying, J.; Tang, X.; Hruby, V. J. Tetrahedron
Lett. 2003, 44, 5863-5866.
(4) Nagula, G.; Urban, J.; Kim, H.-O.; Lum, C.; Nakanishi, H. WO,
03/030907, 2003.
(5) Reyes, S. J.; Burgess, K. Tetrahedron: Asymmetry 2005, 16,
1061-1069.
(6) Lee, H. B.; Zaccaro, M. C.; Pattarawarapan, M.; Roy, S.; Saragovi,
H. U.; Burgess, K. J. Org. Chem. 2004, 69, 701-713.
(7) Lee, H. B.; Pattarawarapan, M.; Roy, S.; Burgess, K. Chem.
Commun. 2003, 1674-1675.
(11) Kahn, M.; Wilke, S.; Chen, B.; Fujita, K. J. Am. Chem. Soc.
1988, 110, 1638-1639.
(8) Pattarawarapan, M.; Zaccaro, M. C.; Saragovi, U.; Burgess, K.
J. Med. Chem. 2002, 45, 4387-4390.
(9) Burgess, K. Acc. Chem. Res. 2001, 34, 826-835.
(10) Cordero, F. M.; Pisaneschi, F.; Batista, K. M.; Valenza, S.;
Machett, F.; Brandi, A. J. Org. Chem. 2005, 70, 856-867.
(12) Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem., Int.
Ed. 2001, 40, 2004-2021.
(13) Cheng, S.; Comer, D. D.; Williams, J. P.; Myers, P. L.; Boger,
D. L. J. Am. Chem. Soc. 1996, 118, 2567-2573.
10.1021/jo0516180 CCC: $30.25 © 2005 American Chemical Society
Published on Web 10/19/2005
J. Org. Chem. 2005, 70, 9595-9598
9595